Table 2.

Efficacy of three artemisinin-containing combinations therapy in comparison with amodiaquine + sulphadoxine–pyrimethamine (AQ-SP) on day 28 after PCR correction, per-protocol analysis

		AS-SMP N = 54	AS-AQ N = 59	AL N = 52	AQ-SP N = 57	p-value
Per protocol analysis (with PCR correction)
	ETF
	n % (95% CI)	1 2% (0–10)	0 0% (0–6)	0 0% (0–7)	0 0% (0–6)
	LCF
	n % (95% CI)	2 4% (0–13)	3 5% (1–14)	2 4% (0–13)	0 0% (0–6)
	LPF
	n % (95% CI)	1 2% (0–10)	1 2% (0–9)	2 4% (0–13)	0 0% (0–6)
	ACPR					0.133
	n % (95% CI)	50 93% (82–98)	55 93% (84–98)	52 92% (81–98)	57 100% (94–100)
Intention to treat analysis (without PCR correction)
	ETF
	n % (95% CI)	1 2% (0–9)	0 0% (0–5)	0 0% (0–6)	0 0% (0–6)
	LCF
	n % (95% CI)	6 10% (4–21)	3 4% (1–12)	2 3%(0–12)	0 0% (0–6)
	LPF
	n % (95% CI)	1 2% (0–9)	1 1% (0–8)	3 5% (1–14)	1 2% (0–8)
	ACPR
	n % (95% CI)	48 83% (71–91)	55 81% (70–89)	48 80% (68–89)	57 88%(77–95)	0.058

AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine (Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number; CI, Confidence interval.